Jeff Jones
Stock Analyst at Oppenheimer
(4.65)
# 813
Out of 4,696 analysts
286
Total ratings
44.7%
Success rate
17.6%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintained: Buy | $55 → $37 | $10.35 | +257.49% | 15 | Sep 2, 2026 | |
| AAPG Ascentage Pharma Group International | Maintained: Buy | $45 | $17.00 | +164.71% | 2 | Aug 21, 2026 | |
| PMVP PMV Pharmaceuticals | Maintained: Buy | $5 | $1.26 | +296.83% | 17 | Aug 17, 2026 | |
| MDWD MediWound | Maintained: Buy | $32 → $30 | $13.06 | +129.71% | 6 | Aug 14, 2026 | |
| PTHS Pelthos Therapeutics | Reiterated: Buy | $66 → $64 | $25.03 | +155.69% | 9 | Aug 14, 2026 | |
| ACRV Acrivon Therapeutics | Maintained: Buy | $8 | $2.15 | +272.09% | 2 | Aug 13, 2026 | |
| AVBP ArriVent BioPharma | Maintained: Buy | $50 | $30.51 | +63.88% | 9 | Aug 13, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $3.10 | +319.35% | 32 | Aug 11, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $52 → $48 | $11.48 | +318.12% | 24 | Aug 7, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $33 | $14.20 | +132.39% | 18 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $11 | $4.30 | +155.81% | 1 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $26.62 | +50.26% | 2 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $2.73 | +815.75% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $35.17 | +42.17% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $6.18 | +61.81% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $4.71 | +48.62% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 → $40 | $11.20 | +257.14% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $37.37 | +130.13% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.43 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $118.63 | +1.15% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $5.67 | n/a | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $5.95 | n/a | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.16 | n/a | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.54 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.95 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.694 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.8602 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.8326 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.07 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.001 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $52.90 | n/a | 1 | Jun 22, 2021 |
Alumis
Sep 2, 2026
Maintained: Buy
Price Target: $55 → $37
Current: $10.35
Upside: +257.49%
Ascentage Pharma Group International
Aug 21, 2026
Maintained: Buy
Price Target: $45
Current: $17.00
Upside: +164.71%
PMV Pharmaceuticals
Aug 17, 2026
Maintained: Buy
Price Target: $5
Current: $1.26
Upside: +296.83%
MediWound
Aug 14, 2026
Maintained: Buy
Price Target: $32 → $30
Current: $13.06
Upside: +129.71%
Pelthos Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $66 → $64
Current: $25.03
Upside: +155.69%
Acrivon Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $8
Current: $2.15
Upside: +272.09%
ArriVent BioPharma
Aug 13, 2026
Maintained: Buy
Price Target: $50
Current: $30.51
Upside: +63.88%
Perspective Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $13
Current: $3.10
Upside: +319.35%
Corbus Pharmaceuticals Holdings
Aug 7, 2026
Reiterated: Buy
Price Target: $52 → $48
Current: $11.48
Upside: +318.12%
Corvus Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: $33
Current: $14.20
Upside: +132.39%
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $4.30
Upside: +155.81%
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $26.62
Upside: +50.26%
May 15, 2026
Maintained: Buy
Price Target: $25
Current: $2.73
Upside: +815.75%
May 13, 2026
Reiterated: Buy
Price Target: $50
Current: $35.17
Upside: +42.17%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $6.18
Upside: +61.81%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.71
Upside: +48.62%
May 8, 2026
Maintained: Buy
Price Target: $41 → $40
Current: $11.20
Upside: +257.14%
Apr 20, 2026
Maintained: Buy
Price Target: $86
Current: $37.37
Upside: +130.13%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.43
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $118.63
Upside: +1.15%
Aug 15, 2025
Maintained: Buy
Price Target: $17 → $16
Current: $5.67
Upside: n/a
Aug 14, 2025
Maintained: Buy
Price Target: $19 → $20
Current: $5.95
Upside: n/a
Aug 8, 2025
Maintained: Hold
Price Target: n/a
Current: $1.16
Upside: n/a
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.54
Upside: n/a
Aug 14, 2024
Maintained: Hold
Price Target: n/a
Current: $5.95
Upside: n/a
Nov 30, 2023
Maintained: Buy
Price Target: n/a
Current: $0.694
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: n/a
Current: $0.8602
Upside: n/a
Nov 7, 2023
Maintained: Buy
Price Target: n/a
Current: $0.8326
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.07
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.001
Upside: n/a
Jun 22, 2021
Maintained: Buy
Price Target: $37
Current: $52.90
Upside: n/a